Prostatectomy News and Research

RSS

Findings allay prostatectomy eye pressure concerns

A Japanese study shows that intraocular pressure increases during robotic-assisted radical prostatectomy with the patient in a steep Trendelenburg position, but this is not associated with an increased risk for postoperative complications or changes in visual function.

18 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Financial interests ‘driving IMRT uptake for prostate cancer’

A study suggests that the recent rapid uptake of intensity-modulated radiotherapy for prostate cancer in the USA has been driven by urologists with financial conflicts of interest.

5 Nov 2013

Overweight men diagnosed with prostate cancer more likely to die from the disease

Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.

30 Oct 2013

Nerve-sparing quality boosts urinary recovery after radical prostatectomy

The quality of nerve sparing during radical prostatectomy has a significant influence on the recovery of urinary function in men with prostate cancer, research shows.

28 Oct 2013

Smoking detriment to long-term prostate cancer outcomes

A US study indicates that men with prostate cancer who smoke at the time of undergoing radical prostatectomy have more aggressive cancers at baseline and poorer long-term outcomes than nonsmokers.

21 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

PSA mass ratio shows prognostic power in localized prostate cancer

Research shows that pathologic prostate-specific antigen mass ratio is a significant predictor for biochemical recurrence-free survival following radical prostatectomy for localized prostate cancer in patients with negative surgical resection margins.

8 Oct 2013

Researchers show that men experience more harm than good from routine PSA screening

Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm than good from routine PSA screening, according to research to be presented on Monday by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC2013).

1 Oct 2013

Tool guides lymph node surgery in Asian prostate cancer patients

Researchers from Korea have developed a nomogram that predicts which Asian men with prostate cancer are most at risk for lymph node (LN) invasion.

30 Sep 2013

Men with prostate cancer experience more harm than good from routine PSA screening

Prostate cancer screening using the prostate-specific antigen test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm than good from routine PSA screening, according to research to be presented today (Monday) by Professor Mathieu Boniol, at the 2013 European Cancer Congress.

30 Sep 2013

Genomic instability in CFS is associated with less favorable outcome in patients with CaP

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image-guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

27 Sep 2013

Researchers identify existence of precursor cells in early prostate cancers

A team of cancer researchers at the University of California, San Diego has identified the existence of precursor cells in early prostate cancers. These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer.

26 Sep 2013

Guideline focuses on radiation therapy to be highlighted during ASTRO's 55th Annual Meeting

The American Society for Radiation Oncology will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO's 55th Annual Meeting, September 22-25, 2013, in Atlanta.

24 Sep 2013

Gene panel predicts low-risk prostate cancer fate

Researchers from the USA have identified a three-gene signature that can predict prostate cancer progression in low Gleason score tumors.

16 Sep 2013

Metamark reports positive results from clinical validation study of prostate cancer prognostic test

Metamark Genetics, Inc., a privately-held biotechnology company, today announced positive results from a large clinical validation study of ProMark, its biopsy-based prostate cancer prognostic test.

10 Sep 2013

Pathologist experience critical for accurate Gleason score

Researchers from Hungary have found that concordance between the preoperative and postoperative staging of prostate cancer in patients undergoing radical prostatectomy increases with pathologist experience.

9 Sep 2013

Seven researchers to receive grants from ASTRO to advance radiation oncology research

The American Society for Radiation Oncology (ASTRO) has selected seven (7) leading researchers who will receive a total of $675,000 in awards and grants to advance radiation oncology research.

23 Aug 2013

PSA screening shows low-grade prostate cancers do not progress to higher grade over time

Prostate cancer aggressiveness may be established when the tumor is formed and not alter with time, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

14 Aug 2013

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.

10 Jul 2013